NexGel, Inc. (NXGL) Q1 2025 Filing Summary
Business Context and Reporting Period
This summary covers NexGel, Inc.'s Form 10-Q for the quarterly period ended March 31, 2025. NexGel manufactures high water content, electron beam cross-linked hydrogels for wound care, medical diagnostics, and cosmetics. The company operates through two primary segments: the NexGel segment (manufacturing and branded consumer products including MedaGel, Kenkoderm, and Silly George) and the CGN segment (a 50% joint venture for converting and packaging). The company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenue | $2,806,000 | $1,266,000 |
| Gross Profit | $1,188,000 | $160,000 |
| Gross Margin | 42.3% | 12.6% |
| Net Loss (Attributable to NexGel) | $(712,000) | $(853,000) |
| Net Loss Per Share (Basic/Diluted) | $(0.09) | $(0.14) |
| Cash and Cash Equivalents | $1,192,000 | $2,419,000 (End of Q1 2024) |
| Working Capital | $2,221,000 | $2,644,000 (End of 2024) |
| Total Debt (Notes Payable + Leases) | $1,020,000 | $1,051,000 (End of 2024) |
Note: Total Debt calculated as sum of current/long-term notes payable and financing lease liabilities.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 121.6% year-over-year, driven primarily by the Silly George acquisition (closed May 2024) and growth in branded consumer products, which generated $1.782 million in revenue compared to $617,000 in Q1 2024.
- Expense Increases: Selling, General, and Administrative (SG&A) expenses rose 90.9% to $1.964 million. This was largely due to a 371.3% increase in advertising and Amazon fees ($641,000 vs. $136,000) and a 215.7% increase in share-based compensation ($161,000 vs. $51,000).
- Profitability: While the company remains unprofitable, the net loss attributable to stockholders narrowed by 16.5% to $(712,000), aided by a $91,000 gain from changes in the fair value of warrant liability.
- Cash Flow: Net cash used in operating activities improved significantly to $(400,000) from $(1,092,000) in the prior year. However, cash balances decreased by $615,000 during the quarter due to operating losses and financing outflows (including a $178,000 payment of contingent consideration).
Outlook, Risks, and Contingencies
- Going Concern: Management has raised substantial doubt about the company's ability to continue as a going concern. The company has an accumulated deficit of $18.7 million and expects to continue incurring losses. Future operations depend on raising additional capital through debt or equity.
- Legal Proceedings: On April 9, 2025, NexGel filed a declaratory judgment lawsuit against Kiss Nail Products, Inc. regarding a patent dispute over Silly George eyelash products. A loss could result in the removal of these products from Amazon, materially affecting the business.
- Internal Controls: The company disclosed that its disclosure controls and procedures were not effective as of March 31, 2025, due to material weaknesses in journal entry approvals and user access rights. Remediation is expected by September 30, 2025.
- Strategic Focus: Management plans to expand sales channels in cosmetics and medical devices and is evaluating strategic acquisitions. No specific financial guidance was provided for the full year 2025.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $1.19 million cash balance against the current burn rate of approximately $400,000 per quarter in operating cash usage.
- Legal Risk: Monitor the status of the patent litigation against Kiss Nail Products, as it directly impacts the high-growth Silly George brand.
- Capital Needs: Assess the likelihood and terms of future capital raises required to fund operations and potential acquisitions.
- Customer Concentration: Review the impact of the top two customers, who held 75% of total accounts receivable as of March 31, 2025.
- Control Remediation: Track the progress of remediation efforts for the identified material weaknesses in internal controls over financial reporting.